![Michel Ducreux](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michel Ducreux
Corporate Officer/Principal en Arch Oncology, Inc. .
Cargos activos de Michel Ducreux
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Arch Oncology, Inc.
![]() Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Corporate Officer/Principal | - | - |
Historial de carrera de Michel Ducreux
Estadísticas
Internacional
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 1 |
Sectorial
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Arch Oncology, Inc.
![]() Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
- Bolsa de valores
- Insiders
- Michel Ducreux
- Experiencia